amaxa and QIAGEN to co-market NucleofectorTM technology and HPP grade siRNA enabling RNA interference in primary cells
Advertisement
amaxa GmbH announced that they have signed an agreement with QIAGEN N.V. to actively co-market amaxa's innovative non-viral Nucleofector(TM) technology with QIAGEN's HPP (High Performance Purity) grade siRNA oligonucleotides based on patented TOM-Amidite chemistry for effective and reproducible gene silencing to the life science markets.
amaxa´s Nucleofector(TM) technology is a highly efficient and reliable tool for the transfection of siRNA oligonucleotides and siRNA vectors into primary cells, hard-to-transfect and commonly used cell lines.
QIAGEN has a leading position in siRNA synthesis technologies based on its patented TOM-Amidite chemistry. As a licensed supplier QIAGEN provides HPP grade siRNA, high throughput siRNA oligonucleotide synthesis services and a large library of predeveloped siRNA molecules directed against common target genes including cancer related genes and the SARS-Coronavirus siRNA Set.
"We are very pleased that amaxa and QIAGEN partnered to exploit synergies in the RNAi field," stated Rainer Christine, amaxa's CEO. "The combination of QIAGEN's siRNA know-how with our ability to transfect suspension cell lines and primary cells with siRNA oligonucleotides enables us to offer to our customers a complete package for the successful knock-down of specific genes."
"We are very excited about amaxa's non-viral transfection technology, which will definitely enhance the range of cell types to be used in gene silencing experiments," said Dr. Ulrich Schriek, QIAGEN's Vice President of Corporate Business Development. "QIAGEN's siRNA products combined with amaxa's transfection technology represent a fully integrated solution in the field of suspension cells including primary cells like primary human T and B cells and cell lines."
The efficient non-viral transfer of small interfering RNAs (siRNAs) into cells has so far been restricted to easy-to-transfect cell lines. With amaxa´s NucleofectorTM technology siRNA-induced gene silencing can easily be achieved in primary cells and hard-to-transfect cell lines.
Primary cells resemble the situation in the living organism, their use for gene silencing experiments accelerates and increases the value for applications such as target validation, gene discovery or gene therapeutic approaches and may lead to powerful new gene-specific siRNA-based therapeutics.
The NucleofectorTM technology is an excellent method to achieve these goals in an easy, effective and reproducible way.
Other news from the department research and development
Most read news
More news from our other portals
Last viewed contents
Inex Pharmaceuticals Announces Appeal Date for Spin-out of Tekmira Pharmaceuticals
Dharmacon's completion of first human genome-wide siRNA library signals new era in life-science research
Sequenom and NAFTNet to Conduct Fetal Rhesus D Study in Collaboration with Baylor College of Medicine
LFE Laboratorium für industrielle Forschung GmbH & Co. Entwicklungs KG - Bruchköbel, Germany
Andromeda Biotech Successfully Completes Patient Recruitment in Phase III Trials for DiaPep277 for Type 1 Diabetes
Bonnie Bassler and Martin Wikelski receive Max Planck Research Award - Scientists honoured for their pioneering research into the sensory perception of organisms
Stora Enso and Gasum to make renewable energy from wastewater in Sweden
LDC and HZI enter partnership for the discovery of new drugs against multi-resistant bacteria
New model could revolutionise the treatment of autoimmune disease as well as vaccine development - Paradigm shift in immunology: 'Adaptive Tolerance' balances autoimmune reaction
Generex Biotechnology and Pevion Biotech announce plans for immunotherapeutic vaccine collaboration
Successful Outcome from European Clinical Pharmacokinetic Study Comparing SUBA-Itraconazole with Sporanox - HalcyGen to begin Marketing Authorisation Application for Regulators in Europe
